Supernus Pharmaceuticals (FRA:S49) FFO


FRA:S49 Supernus Pharmaceuticals Inc FRA:S49
86 GF Score
Price €39.20
GF Value €33.96
Valuation Fairly Valued
View Full Analysis

What is Supernus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:S49
86GF Score
Supernus Pharmaceuticals Inc FRA:S49
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Supernus Pharmaceuticals (FRA:S49) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of €39.20 is trading 15.4% above its estimated GF Value™ of €33.96. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:S49:

  • FFO:
  • GF Value™: €33.96 vs. price of €39.20 (15.4% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the FRA:S49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USA0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
86GF Score

Get the complete analysis for FRA:S49

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.20
Price
€33.96
GF Value